Back to top
more

Accuray (ARAY)

(Delayed Data from NSDQ)

$1.62 USD

1.62
1,533,635

+0.08 (5.19%)

Updated May 3, 2024 04:00 PM ET

After-Market: $1.62 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value F Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (150 out of 252)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Thermo Fisher (TMO) Q3 Earnings Top Estimates, Margins Down

by Zacks Equity Research

Robust demand for Thermo Fisher's (TMO) laboratory products and biopharma services buoys optimism. However, lower Life Sciences Solutions segment revenues in the third quarter disappoint.

Philips' (PHG) Q3 Earnings Down on Supply Chain Constraints

by Zacks Equity Research

Koninklijke Philips' (PHG) Q3 top and bottom-line results reflect the negative impact of supply chain constraints, COVID lockdowns in China and the Russia-Ukraine war.

Accuray's (ARAY) New Treatment Package to Boost Patient Outcome

by Zacks Equity Research

Accuray's (ARAY) latest automated breast cancer treatment package for the Radixact System is expected to extend and improve the quality of patients' lives.

3 Reasons to Hold Accuray (ARAY) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Accuray (ARAY) owing to strong demand for its products.

Accuray's (ARAY) Latest Collaboration to Improve Patient Care

by Zacks Equity Research

Accuray (ARAY) partners with Genolier Innovation Hub to unite companies from the MedTech, pharma and biosciences sectors with physicians and scientists for better patient outcomes.

Are Options Traders Betting on a Big Move in Accuray (ARAY) Stock?

by Zacks Equity Research

Investors need to pay close attention to Accuray (ARAY) stock based on the movements in the options market lately.

Accuray (ARAY) Q4 Earnings Beat Estimates, Margins Down

by Zacks Equity Research

Despite solid Product revenues, Accuray (ARAY) reports an overall soft Q4 performance.

Accuray (ARAY) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Accuray (ARAY) delivered earnings and revenue surprises of 33.33% and 4.93%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

ClearPoint Neuro, Inc. (CLPT) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

ClearPoint Neuro, Inc. (CLPT) delivered earnings and revenue surprises of 0% and 0.70%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Si-Bone (SIBN) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Si-Bone (SIBN) delivered earnings and revenue surprises of -10.20% and 1.85%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

3 Reasons to Add Accuray (ARAY) Stock to Your Portfolio Now

by Zacks Equity Research

Investors continue to be optimistic about Accuray (ARAY) owing to strong demand for its products.

Here's Why You Should Hold on to Accuray (ARAY) Stock For Now

by Zacks Equity Research

Investors continue to be optimistic about Accuray (ARAY) owing to its solid global reach.

Accuray's (ARAY) New Tie-Up to Augment Treatment Planning

by Zacks Equity Research

Accuray (ARAY) partners with Limbus AI to enhance the treatment planning process and patient care.

Down 20% in 4 Weeks, Here's Why Accuray (ARAY) Looks Ripe for a Turnaround

by Zacks Equity Research

Accuray (ARAY) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Accuray (ARAY) Q3 Earnings Beat Estimates, Revenues Lag

by Zacks Equity Research

Despite strong product demand, Accuray (ARAY) reports an overall soft Q3 performance.

Accuray (ARAY) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Accuray (ARAY) delivered earnings and revenue surprises of 83.33% and 3.35%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Accuray's (ARAY) CyberKnife Effective for Relief From TN Pain

by Zacks Equity Research

Latest data indicates that Accuray's (ARAY) CyberKnife System is effective in providing long-lasting pain relief to patients suffering from TN.

3 Reasons to Retain Accuray (ARAY) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Accuray (ARAY) owing to its solid global reach.

New Strong Sell Stocks for March 21st

by Zacks Equity Research

ARAY, AKU, and ANIK have been added to the Zacks Rank #5 (Strong Sell) List on March 21, 2022

Accuray's (ARAY) CyberKnife S7 System Gets Chosen by CARTI

by Zacks Equity Research

Accuray's (ARAY) CyberKnife S7 System gets selected by the CARTI medical care team, thereby offering better cancer care in Arkansas via expanded access to advanced technology.

Why Is Accuray (ARAY) Up 2.6% Since Last Earnings Report?

by Zacks Equity Research

Accuray (ARAY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Accuray (ARAY) Q2 Earnings Miss Estimates, Margins Down

by Zacks Equity Research

Accuray (ARAY) registers growth in Products revenues during fiscal Q2, thereby partly driving its overall top line.

New Strong Sell Stocks for January 27th

by Zacks Equity Research

ARAY, XAIR, and EMKR have been added to the Zacks Rank #5 (Strong Sell) List on January 27, 2022

Accuray (ARAY) Reports Break-Even Earnings for Q2

by Zacks Equity Research

Accuray (ARAY) delivered earnings and revenue surprises of -100% and 10.84%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Accuray (ARAY) Q2 Earnings Expected to Decline

by Zacks Equity Research

Accuray (ARAY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.